Content about Diabetes

December 5, 2013

Regular visits to the doctor, keeping a strict fitness routine and dieting are perceived to be the most important elements in managing and preventing diabetes, according to a recent online survey of more than 500 AccentHealth viewers with diabetes or a family history of diabetes. As many as 94% of respondents visited their doctor regularly, and the same number of respondents exercised regularly. To see more Patient Views, click here.

Regular visits to the doctor, keeping a strict fitness routine and dieting are perceived to be the most important elements in managing and preventing diabetes, according to a recent online survey of more than 500 AccentHealth viewers with diabetes or a family history of diabetes. As many as 94% of respondents visited their doctor regularly, and the same number of respondents exercised regularly. To see more Patient Views, click here.

December 5, 2013

Among diabetes sufferers and those with a diabetic in their household, the critical role of the physician in condition management is most visible, according to a recent online survey of more than 500 AccentHealth viewers. Eight-in-10 indicate their doctor is very or somewhat involved in their own or their household member's diabetes management; half report their doctor is their primary source for condition info — 43% more than those using the second-most common source, health-related web sites.

Among diabetes sufferers and those with a diabetic in their household, the critical role of the physician in condition management is most visible, according to a recent online survey of more than 500 AccentHealth viewers. Eight-in-10 indicate their doctor is very or somewhat involved in their own or their household member's diabetes management; half report their doctor is their primary source for condition info — 43% more than those using the second-most common source, health-related web sites.

December 5, 2013

Making regular doctor appointments is the activity done most often by respondents (78%) to live a healthy life, at least 10 percentage points higher than diet and exercise, according to a recent online survey of more than 500 AccentHealth viewers with diabetes or a family history of diabetes. As many as 70% limit alcohol consumption, and 68% monitor their diet.

Making regular doctor appointments is the activity done most often by respondents (78%) to live a healthy life, at least 10 percentage points higher than diet and exercise, according to a recent online survey of more than 500 AccentHealth viewers with diabetes or a family history of diabetes. As many as 70% limit alcohol consumption, and 68% monitor their diet.To see more Patient Views, click here.

March 27, 2012

In November 2011, The Drug Store News Group hosted in New York an exclusive roundtable discussion of leading pharmacy retailers and a handful of key vendors. Moderated by special guest Dave Wendland of Hamacher Resource Group, the panel tackled a wide range of issues surrounding diabetes management and much more.

In November 2011, The Drug Store News Group hosted in New York an exclusive roundtable discussion of leading pharmacy retailers and a handful of key vendors.

April 17, 2014

Rates of five major diabetes-related complications have declined substantially in the last 20 years among U.S. adults with diabetes, according to a study by the Centers for Disease Control and Prevention, published in the current issue of the New England Journal of Medicine.

ATLANTA — Rates of five major diabetes-related complications have declined substantially in the last 20 years among U.S. adults with diabetes, according to a study by the Centers for Disease Control and Prevention, published in the current issue of the New England Journal of Medicine.

April 16, 2014

Cases of diabetes and pre-diabetes in the United States have nearly doubled since 1988, suggests new research released Tuesday from the Johns Hopkins Bloomberg School of Public Health, with obesity apparently to blame for the surge.

BALTIMORE — Cases of diabetes and pre-diabetes in the United States have nearly doubled since 1988, suggests new research released Tuesday from the Johns Hopkins Bloomberg School of Public Health, with obesity apparently to blame for the surge. The researchers also found that the burden of the disease has not hit all groups equally, with alarming increases in diabetes in blacks, Hispanics and the elderly.

April 15, 2014

The Food and Drug Administration on Tuesday announced that it approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday announced that it has approved Tanzeum (albiglutide) subcutaneous injection, which is used to improve glycemic control in adults with Type 2 diabetes.

Type 2 diabetes affects approximately 24 million people and accounts for more than 90% of diabetes cases diagnosed in the United States.

April 9, 2014

Omnis Health on Tuesday announced the launch of EmbracePro, a blood-glucose meter for medical professionals.

NASHVILLE, Tenn. — Omnis Health on Tuesday announced the launch of EmbracePro, a blood-glucose meter for medical professionals. Approved for multi-patient use, EmbracePro features a test strip release button for more hygienic strip disposal and provides accurate results within five seconds. 

April 3, 2014

MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.

VALENCIA, Calif. — MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes. 

March 28, 2014

Novo Nordisk on Friday launched "Cities Changing Diabetes," a new partnership program to fight the urban diabetes challenge.

BAGSVAERD, Denmark — Novo Nordisk on Friday launched "Cities Changing Diabetes," a new partnership program to fight the urban diabetes challenge. The "Cities Changing Diabetes"program will first be launched in Mexico City, with other cities in North America, Europe and Asia soon to follow.

March 27, 2014

At the American Pharmacists Association Convention on Thursday, PrescribeWellness announced a partnership with the APhA Foundation to provide community pharmacies new tools to help their diabetic patients improve their disease management and health.

ORLANDO, Fla. — At the American Pharmacists Association Convention on Thursday, PrescribeWellness announced a partnership with the APhA Foundation to provide community pharmacies new tools to help their diabetic patients improve their disease management and health.

March 26, 2014

In a study that included nearly 300,000 adults without a known history of diabetes or cardiovascular disease, adding information about glycated hemoglobin (HbA1c), a measure of longer-term blood sugar control, to conventional CVD risk factors like smoking and cholesterol was associated with little improvement in the prediction of CVD risk, according to a study in the March 26 issue of JAMA.

CHICAGO — In a study that included nearly 300,000 adults without a known history of diabetes or cardiovascular disease, adding information about glycated hemoglobin (HbA1c), a measure of longer-term blood sugar control, to conventional CVD risk factors like smoking and cholesterol was associated with little improvement in the prediction of CVD risk, according to a study in the March 26 issue of JAMA.

March 17, 2014

Abbott voluntarily recalled the FreeStyle Blood Glucose Meter and the FreeStyle Flash Blood Glucose Meter, neither of which have been in production since 2010.

ALAMEDA, Calif. — Abbott on Friday voluntarily recalled the FreeStyle Blood Glucose Meter and the FreeStyle Flash Blood Glucose Meter, neither of which have been in production since 2010. Other Abbott Diabetes Care meters are not affected by the recall. 

When used with the Abbott FreeStyle test strips, the FreeStyle Blood Glucose Meter and the FreeStyle Flash Blood Glucose Meter may produce mistakenly low blood glucose results. Abbott began notifying users on Feb. 19, 2014, immediately after the issue was discovered.

March 6, 2014

Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.

LIVERPOOL, England — Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.

However, more than three-quarters of people with diabetes in the United Kingdom (78%) have never attended a diabetes education program, and family members are rarely included (79%). Additionally, only 14% of healthcare professionals say that all their patients with diabetes are offered structured diabetes education classes.

March 3, 2014

AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

WILMINGTON, Del. — AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

The Bydureon pen is a pre-filled, single-use pen injector, which eliminates the need for the patient to transfer their medication between a vial and syringe during the process of self-injection. The pen contains the same formula and dose as the original Bydureon single-dose tray.

March 3, 2014

An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday.

CAMBRIDGE, Mass. — An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday. The results focus the search for developing novel therapeutic strategies for Type 2 diabetes — if a drug can be developed that mimics the protective effect of these mutations, it could open up new ways of preventing this devastating disease.

February 28, 2014

Pharma Supply earlier this week launched NeedleBay, a safe and easy method of organizing and dispensing insulin pen needles and medication.

WEST PALM BEACH, Fla. — Pharma Supply earlier this week launched NeedleBay, a safe and easy method of organizing and dispensing insulin pen needles and medication.

NeedleBay provides a highly visible, unique and simple “proof of use” reminder, which eliminates the risk of missed, or excess injections and associated medications. NeedleBay has been specially designed in consultation with healthcare professionals and those with diabetes, to enable the user to deploy disposable pen needles safely and to avoid the risk of needle pick injuries.

February 25, 2014

The Food and Drug Administration has approved Myalept (metreleptin for injection) to treat complications of leptin deficiency in patients with congenital generalized or acquired generalized lipodystrophy, a condition associated with a lack of fat tissue.

SILVER SPRING, Md. — The Food and Drug Administration has approved Myalept (metreleptin for injection) to treat complications of leptin deficiency in patients with congenital generalized or acquired generalized lipodystrophy, which is a condition associated with a lack of fat tissue.

February 12, 2014

America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday.

WASHINGTON — America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday. These medicines in development — all either in clinical trials or under review by the Food and Drug Administration — include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions.

February 7, 2014

The United States Hispanic Chamber of Commerce welcomed Boehringer Ingelheim Pharmaceuticals to its family of corporate members as a strategic partner.

WASHINGTON — The United States Hispanic Chamber of Commerce on Thursday welcomed Boehringer Ingelheim Pharmaceuticals to its family of corporate members as a strategic partner. "Boehringer Ingelheim's commitment to educating the Hispanic community on the impact of chronic disease is particularly noteworthy," the group noted. "Their dedication to community health was highlighted during last year's launch of a highly successful initiative, in partnership with Univision, that promoted best practices for preventing and treating diabetes.

January 24, 2014

Perrigo announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets.

DUBLIN — Perrigo Co. announced that it received final approval from the Food and Drug Administration for repaglinide tablets — a generic version of Prandin tablets — in 1-mg and 2-mg strengths. The company has started shipment of the drug. Perrigo previously launched the 0.5-mg strength in 2013.

January 23, 2014

Mylan announced that its U.S.-based subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin.

PITTSBURGH — Mylan on Thursday announced that its subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin. The drug is used to improve glycemic control in adults with Type 2 diabetes mellitus.

Repaglinide tablets in 0.5 mg, 1 mg and 2 mg had sales in the United States of approximately $212.95 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

 

January 22, 2014

A new NPR/Robert Wood Johnson Foundation/Harvard School of Public Health poll found that Latinos in America see diabetes as the biggest health problem for their own families.

BOSTON — A new NPR/Robert Wood Johnson Foundation/Harvard School of Public Health poll released Tuesday found that Latinos in America see diabetes as the biggest health problem for their own families.

Nearly 1-in-5 (19%) Latinos said diabetes is the biggest health problem facing their families. The next most cited problem, cancer, is mentioned by just 1-in-20 Latinos (5%). Diabetes was the biggest health problem reported by both immigrant (16%) and non-immigrant Latinos (22%).

January 21, 2014

Novo Nordisk has launched a new insulin pen designed for children with diabetes.

NEW YORK — Novo Nordisk has launched a new insulin pen designed for children with diabetes.

The new NovoPen Echo is the first and only prefilled pen device in the United States that allows for half-unit dosing in combination with a memory function, the company said.

January 17, 2014

The National Community Pharmacists Association on Thursday expressed its support behind the Diabetic Testing Supply Access Act (S. 1935).

ALEXANDRIA, Va. — The National Community Pharmacists Association on Thursday expressed its support behind the Diabetic Testing Supply Access Act (S. 1935). 

The legislation would allow independent community pharmacies to provide same-day delivery of diabetes testing supplies to Medicare beneficiaries and was introduced by Senss Jerry Moran, R-Kan., and John Thune, R-S.D. 

Since July 1, 2013 community pharmacies have been banned from delivering DTS to beneficiaries, including those who are homebound or in long-term care or assisted living facilities.